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NCI 60-cell panel assay;
AntiproliferationAbstract Several anthrapyrazolone derivatives derived from 7-chloroanthra[1,9-cd]pyrazol-6(2H)-
one and 7-chloro-2-(2-hydroxyethyl)anthra[1,9-cd] pyrazol-6(2H)-one have been prepared by the
addition or substitution nucleophilic reactions and further transformed into extended tetracyclic
systems and fused to different nitrogenheterocyclic rings into the pharmacophore structure moiety.
The compounds synthesized were evaluated for their cytotoxic activity and telomerase activity in
prostate cancer cell line by SRB assay and in human non-small cell lung carcinoma cell line by
TRAP assay, respectively. Compounds 1–6, 13, 14, 16, 17, 19, 21, 23, 28 and 31 were selected by
the NCI and only 1, 4, and 16 represent the GI50, TGI and LC50, respectively. Among them, 1
and 16 exhibited distinctive selectivity of GI50 of 10.498 lM and 4.542 lM over 60 cell lines which
is better than the average GI50 (20.3 lM) for SP600125 (NSC75890). Overall, the test compounds+886 2
nce and
ticancer
2 T.-C. Chen et al.
Please cite this article in press as: Chen, T.-C.
agents. Arabian Journal of Chemistry (2015)exhibited different telomerase and cytotoxic activities and only few compounds displayed antitumor
activity in the low range.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Many clinically successful anticancer drugs are either natural
products or have been developed from naturally occurring lead
compounds, such as taxol, camptothecin (topotecan and
irinotecan), vinblastine, and anthracyclines (doxorubicin and
mitoxantrone). The mechanism of anthracyclines is inhibiting
topoisomerase II through binding a part of the catalytic cycle
of the enzyme to stabilization of the cleavable complex (Suzuki
et al., 1995), and intercalating into the minor groove of double-
strand DNA base pairs via the core planar pharmacophore
group (Wang et al., 1994). It is an amusive class of pyrazole
and pyrazole-fused heterocyclic derivatives because of their
synthetic gifted and efﬁcacious biological activities. Besides,
anthrapyrazole, a kind of anthrathenes having a pyrazole ring,
is a series of structures which has found anticancer activities.
They classiﬁed as alkaloids are rare in nature, but they still
are the important components and have pharmacological
effects on humans. There are several studies found that pyra-
zole derivatives had potent inhibitory activity against inﬂam-
matory (Tewari et al., 2010), bacterium (Genin et al., 2000a;
Kucukguzel et al., 2000), virus (Genin et al., 2000b), adenosine
receptors (Baraldi et al., 2002, 2003), and leukemia cell lines
(Kostakis et al., 2002; Mansour et al., 2003).
Anthrapyrazole represents another successful bioisosterism
lead structure as an alternative approach for antitumor appli-
cation (Krapcho et al., 1995), which structurally related to
mitoxantrone (MX) and its mechanism of action is mainly poi-
soning of the DNA Topoisomerase II enzyme (Faulds et al.,
1991). To overcome the drawback of cardiotoxic effects, a
pyrazole ring is fused to the anthraquinone moiety, giving a
tetracyclic system in an attempt to reduce toxicity or modify
the activity of the lead compound, and may alter the metabo-
lism of the lead (Krapcho et al., 1985, 1994; Gandolﬁ et al.,
1995). Losoxantrone (DUP-941), is an anthrapyrazole deriva-
tive and found that sharing similar pharmacokinetics (Graham
et al., 1992), behaving almost similarly in the in vitro National
Cancer Institute (NCI) cell screen and exhibiting the same anti-
cancer spectrum of activity as MX with reduced cardiotoxicity
(Leteurtre et al., 1994). There were at least two phase II studies
of losoxantrone reported both included untreated and treated
patients with metastatic breast cancer (Talbot et al., 1991) and
prostate cancer (Huan et al., 2000). Simultaneously, one of
DUP 941 analogues, DUP-937 (teloxantrone), is an intercala-
tor and inhibits DNA synthesis which was conducted for phase
I and phase II clinical trials (Renner et al., 1995). SP600125
(NSC75890), prevented cell injury induced by N-Acetyl-p-
Aminophenol (APAP) exposure, is also a famous c-Jun
N-terminal kinase (JNK) inhibitor having middle cytotoxicity
(Fig. 1). To understand the molecular basis for a dramatically
different response by otherwise very similar compounds, we
performed a detailed investigation on the biological activities
of several anthrapyrazoles belonging to the two families, onet al., Synthesis and biological evaluatio
, http://dx.doi.org/10.1016/j.arabjc.2015their cytotoxicity and speciﬁcity as well as on their telomerase
activity.
As stated above, pyrazole systems are involved in a wide
range of biological activities, and for that reason, in addition
to the antineoplastic evaluation, several representative com-
pounds have been prospectively evaluated for their antitumor
potential. The search for additional enzyme inhibitor is con-
ﬁrmed by the extraordinary anticancer activity of pyrazole-
fused and anthraquinones and by the feasibility that different
enzyme poisons would exhibit different activities in cancer
chemotherapy (Huang et al., 2009). According to our previous
studies, a series of disubstituted anthraquinones was showed
the inherent capacity against telomerase inhibition activity
(Huang et al., 2005b, 2005a). In recent years, we hybridized
the anthraquinone and some potent structures and found that
imidazole-fused anthraquinones have potent inhibitory activi-
ties against telomerase (Huang et al., 2008, 2009; T.C. Chen
et al., 2013; C.L. Chen et al., 2013) and poly (ADP-ribose)
polymerase (PARP) (Lee et al., 2013). Thus, we try to design
and synthesize a series of new derivatives which is substituted
at position 7. To ﬁnd such new heterocycle-fused small molec-
ular or pharmacophore targets for anticancer drugs the results
of their biological evaluation are reported and discussed here.
2. Chemistry
2.1. Material and instruments
The methods and physical data of synthesizing compounds 1–
32 were described and all the synthetic compounds were com-
pared to their growth inhibition, cytotoxicity and telomerase
activity. In this investigation, we were dedicated on the role
of our systematic synthesized tetracyclic and heterocyclic phar-
macophore and introduced a series of side chains linked to the
anthra[1,9-cd]pyrazol-6(2H)-one moiety (Scheme 1).
Each reaction was monitored by TLC (silica gel 60 F254)
under standardized UV (254 nm). 1H NMR and 13C NMR
were measured on Varian GEMINI-300 (300 MHz); d values
are in ppm relative to tetramethylsilane (TMS) as an internal
standard. Multiplicities are recorded as s (singlet), d (doublet),
t (triplet), q (quartet), dd (doublet of doublets), m (multiplet),
and br (broadened). High resolution electron impact ioniza-
tion (HREI) was measured on Finnigan MAT MAT-95XL
(Instrumentation Center, National Tsing Hua University,
Hsinchu, Taiwan). Melting points were obtained with a
Bu¨chi B-545 melting point apparatus. Typical experiments
illustrating the synthetic procedures for the preparation of
the anthrapyrazolones are described below.
2.2. Synthetic methods
Thirty-two compounds were synthesized, starting from 1,5-
dichloroanthraquinone. All the organic solvents and chemicaln of anthra [1,9-cd]pyrazol-6(2H)-one scaﬀold derivatives as potential anticancer
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Figure 1 Structural hybridization of some preclinical and clinical anticancer drugs.
Synthesis and biological evaluation of anthra[1,9-cd]pyrazol-6(2H)-one scaffold derivatives 3reactants required for synthesis were purchased from either
Merck Chemical Company or Sigma–Aldrich Chemical
Company without further puriﬁcation.
2.2.1. Synthetic procedure I: Preparation of compound 1
1,5-Dichloroanthraquinone (2.00 g, 7.2 mmol) was dissolved
in DMSO (20 mL) and hydrazine monohydrate (1.5 mL,
30 mmol) and diisopropylethylamine (DIPEA) (2 mL) was
added. The reaction mixture was continued under reﬂuxing
condition for 2 h. The reaction mixture was cooled to room
temperature, treated with crushed ice, neutralized and col-
lected the ethyl acetate (EA) layer by partition. The organic
layer was added anhydrous magnesium sulfate (MgSO4) to
remove the water, dried and washed with dichloromethane
to afford desired compound as a brown solid.
2.2.2. Synthetic procedure II: Preparation of compound 17
1,5-Dichloroanthraquinone (2.00 g, 7.2 mmol) and 2-
hydroxyethylhydrazine (2 mL, 29.5 mmol) were dissolved in
pyridine (20 mL) and stirred at 120 C for 2 h. The reaction
mixture was cooled to room temperature, treated with crushed
ice and neutralized with 5% hydrochloric acid (HCl). And
then, the mixture was partition with ethyl acetate. The organic
layer was dried by anhydrous MgSO4, removed the solventPlease cite this article in press as: Chen, T.-C. et al., Synthesis and biological evaluatio
agents. Arabian Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.2015and washed with dichloromethane to afford desired compound
as a yellow solid.
2.2.3. General procedure III: Preparation of compounds 2–16
and 18–32
Compound 1 or 17 (2 mmol), primary amine (10 mmol) and
N,N-dimethylaminopyridine (DMAP) (2 mmol) were dissolved
in DMSO (10 mL) stirred at room temperature for 4 h. The
reaction was added water (100 mL), neutralized by 5% HCl
and extracted with EA. The resulting precipitate was collected
by ﬁltration, washed with water and puriﬁed by crystallization
from EA/hexane to afford desired compounds.
2.3. Physical data
2.3.1. 7-Chloroanthra[1,9-cd]pyrazol-6(2H)-one (1)
The pure compound was obtained as a brown solid (yield
42%). (Rf = 0.43 at ethyl acetate:n-hexane = 1:1). Mp 310–
311 C (EtOH) (Kim et al., 2003). FT-IR (KBr; m cm1):
3234 (NH), 1637 (CO). 1H NMR (300 MHz, DMSO-d6): d
(ppm) 7.59 (dd, J= 7.8, 1.2 Hz, 1H, Ar–H10), 7.71 (t,
J= 7.5 Hz, 1H, Ar–H4), 7.72 (t, J= 7.8 Hz, 1H, Ar–H9),
7.87 (d, J= 7.2 Hz, 1H, Ar–H3), 7.97 (d, J= 8.1 Hz, 1H,
Ar–H8), 8.21 (dd, J= 7.5, 1.2 Hz, 1H, Ar–H5), 13.82 (br,n of anthra [1,9-cd]pyrazol-6(2H)-one scaﬀold derivatives as potential anticancer
.06.017
Scheme 1 Synthesis of anthrapyrazolones. Reagents and conditions: (i) Hydrazine monohydrate, DMSO, DIPEA, reﬂux, 120 C, 2 h. (ii)
2-Hydroxyethylhydrazine, pyridine, reﬂux, 120 C, 2 h. (iii) Primary amines, DMSO, DMAP, mini-reactor, 120–140 C, 4 h.
4 T.-C. Chen et al.1H, –NH–). 13C NMR (75 MHz, DMSO-d6): d (ppm) 117.12,
120.66, 121.83, 122.20, 126.31, 128.86, 129.15, 132.67, 134.22,
135.21, 136.23, 139.59, 182.29 (C‚O). HRMS (EI) m/z calcd
for C14H7ClN2O




Product 2 was prepared from 1 with isobutylamine. The red
solid material was isolated in 19% yield. (Rf = 0.60 at ethyl
acetate:n-hexane = 1:1). Mp 237–238 C (EtOH). FT-IR
(KBr; m cm1): 3249 (NH), 1622 (C‚O), 1600 (C‚N). 1H
NMR (300 MHz, DMSO-d6): d (ppm) 1.03 (d, J= 6.6 Hz,
6H, –CH3), 1.99 (m, 1H, –CH–), 3.13 (t, J= 6.0 Hz, 2H, –
NCH2–), 6.85 (d, J= 8.7 Hz, 1H, Ar–H10), 7.36 (d,
J= 7.2 Hz, 1H, Ar–H3), 7.51 (t, J= 7.8 Hz, 1H, Ar–H9),
7.64 (t, J= 7.8 Hz, 1H, Ar–H4), 7.79 (d, J= 7.2 Hz, 1H,
Ar–H8), 7.86 (d, J= 8.1 Hz, 1H, Ar–H5), 10.17 (t,Please cite this article in press as: Chen, T.-C. et al., Synthesis and biological evaluatio
agents. Arabian Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.2015J= 5.1 Hz, 1H, –NH–), 13.55 (br, 1H, pyrazole-NH). 13C
NMR (75 MHz, DMSO-d6): d (ppm) 20.56, 27.88, 50.22,
109.20, 112.41, 114.10, 116.31, 119.57, 122.09, 127.15, 128.94,
133.57, 135.67, 139.42, 139.96, 154.08, 187.12 (C‚O).
HRMS (EI) m/z calcd for C18H17N3O
+, [M]+: 291.1372,
found, 248.0815 (100), 291.1367 (15).
2.3.3. 7-(Propylamino)anthra[1,9-cd]pyrazol-6(2H)-one (3)
Product 3 was prepared from 1 with propylamine. The red
solid material was isolated in 34% yield (Rf = 0.58 at ethyl
acetate:n-hexane = 1:1). Mp 247–248 C (EtOH). FT-IR
(KBr; m cm1): 3147 (NH), 1618 (C‚O), 1599 (C‚N). 1H
NMR (300 MHz, Acetone-d6): d (ppm) 1.10 (t, J= 7.5 Hz,
3H, –CH3), 1.74–1.86 (m, 2H, –CH2–), 3.30–3.37 (m, 2H, –
NCH2–), 6.88 (dd, J= 8.1, 1.5 Hz, 1H, Ar–H10), 7.46 (dd,
J= 7.5, 1.5 Hz, 1H, Ar–H3), 7.52 (t, J= 7.8 Hz, 1H, Ar–
H9), 7.66 (t, J= 7.8 Hz, 1H, Ar–H4), 7.85 (d, J= 7.8 Hz,
1H, Ar–H8), 7.85 (d, J= 7.8 Hz, 1H, Ar–H5), 10.17 (br, 1H,n of anthra [1,9-cd]pyrazol-6(2H)-one scaﬀold derivatives as potential anticancer
.06.017
Synthesis and biological evaluation of anthra[1,9-cd]pyrazol-6(2H)-one scaffold derivatives 5–NH–), 12.60 (br, 1H, pyrazole-NH). 13C NMR (75 MHz,
Acetone-d6): d (ppm) 11.75, 22.15, 44.20, 109.16, 112.26,
114.06, 116.16, 119.44, 122.06, 127.12, 128.84, 133.53, 135.56,
139.33, 139.97, 153.86, 186.99 (C‚O). HRMS (EI) m/z calcd
for C17H15N3O




Product 4 was prepared from 1 with 5-amino-1-pentanol. The
red solid material was isolated in 44% yield (Rf = 0.18 at ethyl
acetate:n-hexane = 1:1). Mp 206–207 C (EtOH) (Pang et al.,
2010). FT-IR (KBr; m cm1): 3159 (NH), 3078 (OH), 1602
(C‚O), 1569 (C‚N). 1H NMR (300 MHz, Acetone-d6): d
(ppm) 1.59–1.63 (m, 2H, –CH2–), 1.59–1.63 (m, 2H, –CH2–),
1.77–1.86 (m, 2H, –CH2–), 3.34–3.41 (m, 2H, –NCH2–), 3.47
(s, 1H, –OH), 3.60 (t, J= 4.8 Hz, 2H, –OCH2–), 6.88 (dd,
J= 8.1, 1.8 Hz, 1H, Ar–H10), 7.45 (dd, J= 7.2, 1.5 Hz, 1H,
Ar–H3), 7.52 (t, J= 7.5 Hz, 1H, Ar–H9), 7.66 (t,
J= 7.7 Hz, 1H, Ar–H4), 7.85 (d, J= 7.5 Hz, 1H, Ar–H8),
7.85 (d, J= 7.5 Hz, 1H, Ar–H5), 10.16 (br, 1H, –NH–),
12.61 (br, 1H, pyrazole-NH). 13C NMR (75 MHz, DMSO-
d6): d (ppm) 23.57, 28.84, 32.54, 42.49, 61.04, 109.14, 112.26,
114.04, 116.18, 119.45, 122.05, 127.12, 128.84, 133.52, 135.58,
139.34, 139.96, 153.83, 186.96 (C‚O). HRMS (EI) m/z calcd
for C19H19N3O2




Product 5 was prepared from 1 with phenethylamine. The red
solid material was isolated in 57% yield (Rf = 0.64 at ethyl
acetate:n-hexane = 1:1). Mp 221–222 C (EtOH). FT-IR
(KBr; m cm1): 3178 (NH), 3078 (OH), 1620 (C‚O), 1599
(C‚N). 1H NMR (300 MHz, Acetone-d6): d (ppm) 3.09 (t,
J= 7.2 Hz, 2H, –CH2–), 3.60–3.67 (m, 2H, –NCH2–), 6.97
(d, J= 9.0 Hz, 1H, Ar–H10), 7.23 (t, J= 6.9 Hz, 1H, Ar
0–
H4), 7.34 (t, J= 7.8 Hz, 2H, Ar
0–H3, H5), 7.41 (d,
J= 7.8 Hz, 2H, Ar0–H2,6), 7.49 (t, J= 7.2 Hz, 1H, Ar–H3),
7.50 (t, J= 5.1 Hz, 1H, Ar–H9), 7.66 (t, J= 7.5 Hz, 1H,
Ar–H4), 7.84 (d, J= 3.0 Hz, 1H, Ar–H8), 7.86 (d,
J= 3.9 Hz, 1H, Ar–H5), 10.22 (br, 1H, –NH–), 12.62 (br,
1H, pyrazole-NH). 13C NMR (75 MHz, DMSO-d6): d (ppm)
35.09, 44.02, 109.38, 112.28, 114.20, 116.22, 119.49, 122.05,
126.68, 127.06, 128.83, 129.02, 129.16, 133.53, 135.56, 139.37,
139.72, 139.88, 153.56, 186.91 (C‚O). HRMS (EI) m/z calcd
for C22H17N3O




Product 6 was prepared from 1 with cyclohexylamine. The red
solid material was isolated in 22% yield (Rf = 0.69 at ethyl
acetate:n-hexane = 1:1). Mp 246–247 C (EtOH). FT-IR
(KBr; m cm1): 3145 (NH), 3078 (OH), 1620 (C‚O), 1599
(C‚N). 1H NMR (300 MHz, DMSO-d6): d (ppm) 1.34–2.01
(m, 10H, –(CH2)5), 3.60 (s, 1H, –NCH–), 6.89 (d,
J= 8.1 Hz, 1H, Ar–H10), 7.34 (dd, J= 7.2, 0.9 Hz, 1H, Ar–
H3), 7.49 (t, J= 7.8 Hz, 1H, Ar–H9), 7.63 (t, J= 7.8 Hz,
1H, Ar–H4), 7.77 (d, J= 6.9 Hz, 1H, Ar–H8), 7.85 (d,Please cite this article in press as: Chen, T.-C. et al., Synthesis and biological evaluatio
agents. Arabian Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.2015J= 8.1 Hz, 1H, Ar–H5), 10.21 (d, J= 7.2 Hz, 1H, –NH–),
13.58 (br, 1H, pyrazole-NH). 13C NMR (75 MHz, DMSO-
d6): d (ppm) 24.15, 25.66, 32.60, 49.83, 108.98, 112.74,
113.96, 116.17, 119.43, 122.07, 127.19, 128.87, 133.68, 135.50,
139.38, 139.97, 152.93, 186.97 (C‚O). HRMS (EI) m/z calcd
for C20H19N3O




Product 7 was prepared from 1 with cyclopentylamine. The red
solid material was isolated in 21% yield (Rf = 0.58 at ethyl
acetate:n-hexane = 1:1). Mp 212–213 C (EtOH). FT-IR
(KBr; m cm1): 3149 (NH), 1622 (C‚O), 1602 (C‚N). 1H
NMR (300 MHz, DMSO-d6): d (ppm) 1.54–2.08 (m, 8H, –
(CH2)4–), 3.99–4.01 (m, 1H, –NCH–), 6.87 (d, J= 8.4 Hz,
1H, Ar–H10), 7.36 (d, J= 7.2 Hz, 1H, Ar–H3), 7.51 (t,
J= 7.8 Hz, 1H, Ar–H9), 7.64 (t, J= 7.8 Hz, 1H, Ar–H4),
7.77 (d, J= 6.9 Hz, 1H, Ar–H8), 7.85 (d, J= 8.1 Hz, 1H,
Ar–H5), 10.16 (d, J= 6.3 Hz, 1H, –NH–), 13.57 (br, 1H,
pyrazole-NH). 13C NMR (75 MHz, DMSO-d6): d (ppm)
23.98, 33.42, 53.47, 109.18, 113.13, 114.09, 116.30, 119.53,
122.07, 127.16, 128.94, 133.60, 135.55, 139.42, 139.94, 153.33,
187.00 (C‚O). HRMS (EI) m/z calcd for C19H17N3O
+
[M]+: 303.1372, found, 274.0969 (90), 303.1371 (100).
2.3.8. 7-(Methylcyclohexylamino)anthra[1,9-cd]pyrazol-
6(2H)-one (8)
Product 8 was prepared from 1 with aminomethylcyclohexane.
The brown solid material was isolated in 47% yield (Rf = 0.63
at ethyl acetate:n-hexane = 1:1). Mp 245–246 C (EtOH). FT-
IR (KBr; m cm1): 3177 (NH), 1620 (C‚O), 1600 (C‚N). 1H
NMR (300 MHz, Acetone-d6): d (ppm) 1.10–1.97 (m, 10H, –
(CH2)5–), 1.10–1.97 (m, 1H, –CH–), 3.20 (t, J= 6.0 Hz, 2H,
–NCH2–), 6.87 (dd, J= 8.4, 1.5 Hz, 1H, Ar–H10), 7.46 (dd,
J= 7.5, 1.5 Hz, 1H, Ar–H3), 7.51 (t, J= 7.5 Hz, 1H, Ar–
H9), 7.66 (t, J= 7.8 Hz, 1H, Ar–H4), 7.84 (dd, J= 7.8,
2.0 Hz, 2H, Ar–H8, Ar–H5), 10.28 (br, 1H, –NH–), 12.60
(br, 1H, pyrazole-NH). 13C NMR (75 MHz, DMSO-d6): d
(ppm) 25.73, 26.33, 30.93, 37.33, 48.90, 109.07, 112.32,
114.05, 116.23, 119.48, 122.04, 127.12, 128.85, 133.52, 135.58,
139.35, 139.89, 154.01, 187.01 (C‚O). HRMS (EI) m/z calcd
for C21H21N3O




Product 9 was prepared from 1 with 3-amino-1-propanol. The
red solid material was isolated in 24% yield (Rf = 0.18 at ethyl
acetate:n-hexane = 1:1). Mp 147–149 C (EtOH). FT-IR
(KBr; m cm1): 3163 (NH), 3116 (OH), 1620 (C‚O), 1598
(C‚N). 1H NMR (300 MHz, Acetone-d6): d (ppm) 1.94–
2.02 (m, 2H, –CH2–), 3.45–3.51 (m, 2H, –CH2–), 3.78 (t,
J= 5.7 Hz, 2H, –NCH2–), 6.92 (d, J= 8.7 Hz, 1H, Ar–
H10), 7.47 (d, J= 8.1 Hz, 1H, Ar–H3), 7.52 (t, J= 7.5 Hz,
1H, Ar–H9), 7.66 (t, J= 7.5 Hz, 1H, Ar–H4), 7.85 (d,
J= 7.8 Hz, 2H, Ar–H5,8), 10.18 (br, 1H, –NH–), 12.60 (br,
1H, pyrazole-NH). 13C NMR (75 MHz, DMSO-d6): d (ppm)
32.26, 39.52, 58.77, 109.15, 110.39, 112.27, 113.16, 116.18,
119.43, 125.20, 127.13, 128.86, 129.04, 139.34, 140.41, 153.88,n of anthra [1,9-cd]pyrazol-6(2H)-one scaﬀold derivatives as potential anticancer
.06.017
6 T.-C. Chen et al.186.94 (C‚O). HRMS (EI) m/z calcd for C17H15N3O2
+ [M]+:
293.1164, found, 248.0809 (100), 293.1156 (30).2.3.10. 7-(Butylamino)anthra[1,9-cd]pyrazol-6(2H)-one (10)
Product 10 was prepared from 1 with butylamine. The red
solid material was isolated in 19% yield (Rf = 0.63 at ethyl
acetate:n-hexane = 1:1). Mp 219–220 C (EtOH) (Sokolyuk
et al., 2002). FT-IR (KBr; m cm1): 3153 (NH), 1622 (C‚O),
1604 (C‚N). 1H NMR (300 MHz, Acetone-d6): d (ppm)
1.02 (t, J= 7.5 Hz, 3H, –CH3), 1.50–1.63 (m, 2H, –CH2–),
1.73–1.82 (m, 2H, –CH2–), 3.34–3.40 (m, 2H, –NCH2–), 6.89
(d, J= 6.6 Hz, 1H, Ar–H10), 7.47 (d, J= 6.9 Hz, 1H, Ar–
H3), 7.52 (t, J= 7.8 Hz, 1H, Ar–H9), 7.66 (t, J= 7.8 Hz,
1H, Ar–H4), 7.85 (d, J= 7.5 Hz, 2H, Ar–H5,8), 10.15 (br,
1H, –NH–), 12.62 (br, 1H, pyrazole-NH). 13C NMR
(75 MHz, DMSO-d6): d (ppm) 13.88, 20.06, 30.99, 42.08,
109.13, 112.26, 114.06, 116.17, 119.43, 122.05, 127.10, 128.84,
133.54, 135.58, 139.32, 139.60, 153.85, 186.97 (C‚O).
HRMS (EI) m/z calcd for C18H17N3O
+ [M]+: 291.1372,
found, 248.0816 (100), 291.1365 (25).2.3.11. 7-(Methylamino)anthra[1,9-cd]pyrazol-6(2H)-one
(11)
Product 11 was prepared from 1 with methylamine. The red
solid material was isolated in 14% yield (Rf = 0.60 at ethyl
acetate:n-hexane = 3:2). Mp 254–255 C (EtOH). FT-IR
(KBr; m cm1): 3147 (NH), 1622 (C‚O), 1602 (C‚N). 1H
NMR (300 MHz, Acetone-d6): d (ppm) 3.04 (d, J= 5.1 Hz,
3H, –NCH3), 6.85 (d, J= 8.4 Hz, 1H, Ar–H10), 7.48 (dd,
J= 7.4, 1.5 Hz, 1H, Ar–H3), 7.55 (t, J= 7.5 Hz, 1H, Ar–
H9), 7.66 (t, J= 8.1 Hz, 1H, Ar–H4), 7.84 (d, J= 2.4 Hz,
1H, Ar–H8), 7.87 (d, J= 3.3 Hz, 1H, Ar–H5), 10.01 (br, 1H,
–NH–), 12.62 (br, 1H, pyrazole-NH). 13C NMR (75 MHz,
DMSO-d6): d (ppm) 29.49, 109.23, 111.93, 116.25, 119.40,
127.13, 128.87, 129.06, 129.22, 132.73, 133.47, 134.29, 135.61,
154.61, 186.88 (C‚O). HRMS (EI) m/z calcd for
C15H11N3O
+ [M]+ 249.0902, found, 232.0877 (50), 249.0897
(100).2.3.12. 7-(Benzylamino)anthra[1,9-cd]pyrazol-6(2H)-one
(12)
Product 12 was prepared from 1 with benzylamine. The red
solid material was isolated in 26% yield (Rf = 0.62 at ethyl
acetate:n-hexane = 3:2). Mp 219–220 C (EtOH) (Bennett
et al., 2004). FT-IR (KBr; m cm1): 3153 (NH), 1622 (C‚O),
1600 (C‚N). 1H NMR (300 MHz, Acetone-d6): d (ppm)
4.64 (d, J= 4.5 Hz, 2H, –NCH2–), 6.86 (dd, J= 6.9, 2.4 Hz,
1H, Ar–H10), 7.30 (t, J= 7.2 Hz, 1H, Ar
0–H4), 7.39 (t,
J= 7.5 Hz, 2H, Ar0–H3,5), 7.48 (d, J= 6.3 Hz, 2H, –Ar0–
H2, H6), 7.48 (d, J= 6.3 Hz, 1H, Ar–H3), 7.49 (t,
J= 7.5 Hz, 1H, Ar–H9), 7.66 (t, J= 7.8 Hz, 1H, Ar–H4),
7.85 (d, J= 2.1 Hz, 1H, Ar–H8), 7.88 (d, J= 3.0 Hz, 1H,
Ar–H5), 10.54 (br, 1H, –NH–), 12.65 (br, 1H, pyrazole-NH).
13C NMR (75 MHz, DMSO-d6): d (ppm) 46.43, 109.70,
112.69, 114.54, 116.41, 119.63, 122.06, 127.03, 127.58, 127.74,
128.90, 129.09, 133.59, 135.54, 139.33, 139.40, 139.83, 153.55,
187.16 (C‚O). HRMS (EI) m/z calcd for C21H15N3O
+
[M]+ 325.1215, found, 248.0815 (25), 325.1209 (100).Please cite this article in press as: Chen, T.-C. et al., Synthesis and biological evaluatio
agents. Arabian Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.20152.3.13. 7-[2-(1-Cyclohexenyl)ethylamino]anthra[1,9-
cd]pyrazol-6(2H)-one (13)
Product 13 was prepared from 1 with 2-(1-
cyclohexenyl)ethylamine. The red solid material was isolated
in 31% yield (Rf = 0.69 at ethyl acetate:n-hexane = 3:2).
Mp 213–214 C (EtOH). FT-IR (KBr; m cm1): 3211 (NH),
1622 (C‚O), 1600 (C‚N). 1H NMR (300 MHz, Acetone-
d6): d (ppm) 1.59–1.66 (m, 8H, cyclohexene-(CH2)4), 2.40 (t,
J= 6.6 Hz, 2H, –CH2–), 3.41–3.47 (m, 2H, –NCH2–), 5.67
(s, 1H, cyclohexene-CH–), 6.89 (dd, J= 8.1, 1.5 Hz, 1H, Ar–
H10), 7.46 (dd, J= 7.5, 1.5 Hz, 1H, Ar–H3), 7.52 (t,
J= 7.2 Hz, 1H, Ar–H9), 7.65 (t, J= 8.1 Hz, 1H, Ar–H4),
7.85 (d, J= 7.5 Hz, 1H, Ar–H8), 7.85 (d, J= 7.5 Hz, 1H,
Ar–H5), 10.07 (br, 1H, –NH–), 12.60 (br, 1H, pyrazole-NH).
13C NMR (75 MHz, DMSO-d6): d (ppm) 22.22, 22.73, 25.05,
27.84, 37.15, 41.01, 109.18, 112.35, 114.18, 116.14, 119.40,
122.05, 123.41, 127.12, 128.80, 133.49, 135.01, 135.47, 139.38,
139.91, 153.63, 186.82 (C‚O). HRMS (EI) m/z calcd for
C22H21N3O




Product 14 was prepared from 1 with 2-(4-
methoxyphenyl)ethylamine. The red solid material was
isolated in 42% yield (Rf = 0.57 at ethyl acetate:n-
hexane = 3:2). Mp 219–210 C (EtOH). FT-IR (KBr; m
cm1): 3167 (NH), 1620 (C‚O), 1600 (C‚N). 1H NMR
(300 MHz, Acetone-d6): d (ppm) 3.02 (t, J= 7.5 Hz, 2H,
–CH2–), 3.55–3.61 (m, 2H, –NCH2–), 3.77 (s, 3H, –OCH3),
6.90 (d, J= 8.7 Hz, 4H, Ar0–H), 7.32 (d, J= 8.7 Hz, 1H,
Ar–H10), 7.47 (dd, J= 7.2, 1.5 Hz, 1H, Ar–H3), 7.53 (t,
J= 8.1 Hz, 1H, Ar–H9), 7.65 (t, J= 7.2 Hz, 1H, Ar–H4),
7.84 (d, J= 3.0 Hz, 1H, Ar–H8), 7.86 (d, J= 4.2 Hz, 1H,
Ar–H5), 10.20 (br, 1H, –NH–), 12.61 (br, 1H, pyrazole-NH).
13C NMR (75 MHz, DMSO-d6): d (ppm) 34.21, 44.28, 55.38,
109.34, 112.30, 114.16, 114.36, 116.23, 119.50, 122.05, 127.08,
128.84, 130.14, 131.57, 133.53, 135.59, 139.37, 139.89, 153.59,
158.42, 186.91 (C‚O). HRMS (EI) m/z calcd for
C23H19N3O2




Product 15 was prepared from 1 with 2-methoxybenzylamine.
The red solid material was isolated in 39% yield (Rf = 0.60 at
ethyl acetate:hexane = 3:2). Mp 217–218 C (EtOH). FT-IR
(KBr; m cm1): 3159 (NH), 1622 (C‚O), 1601 (C‚N). 1H
NMR (300 MHz, Acetone-d6): d (ppm) 3.93 (s, 3H, –OCH3),
4.59 (d, J= 5.7 Hz, 2H, –NCH2–), 6.87 (t, J= 5.1 Hz, 1H,
Ar–H10), 6.94 (t, J= 7.8 Hz, 1H, Ar
0–H5), 7.06 (d,
J= 8.1 Hz, 1H, Ar–H3), 7.29 (t, J= 7.8 Hz, 1H, Ar–H9),
7.38 (d, J= 7.8 Hz, 1H, Ar0–H3), 7.47 (d, J= 4.5 Hz, 1H,
Ar0–H6), 7.47 (t, J= 4.5 Hz, 1H, Ar0–H4), 7.66 (t,
J= 7.5 Hz, 1H, Ar–H4), 7.87 (d, J= 7.8 Hz, 1H, Ar–H8),
7.87 (d, J= 7.81 Hz, 1H, Ar–H5), 10.50 (br, 1H, –NH–),
12.63 (br, 1H, pyrazole-NH). 13C NMR (75 MHz, DMSO-
d6): d (ppm) 41.55, 55.87, 109.50, 111.52, 112.47, 114.50,
116.25, 119.55, 120.88, 122.10, 126.73, 127.11, 128.83, 129.02,
129.13, 133.60, 135.50, 139.39, 153.65, 157.69, 187.04n of anthra [1,9-cd]pyrazol-6(2H)-one scaﬀold derivatives as potential anticancer
.06.017





Product 16 was prepared from 1 with piperonylamine. The red
solid material was isolated in 22% yield (Rf = 0.58 at ethyl
acetate:n-hexane = 3:2). Mp 217–218 C (EtOH). FT-IR
(KBr; m cm1): 3173 (NH), 1622 (C‚O), 1600 (C‚N). 1H
NMR (300 MHz, DMSO-d6): d (ppm) 4.45 (d, J= 5.7 Hz,
2H, –NCH2–), 6.00 (s, 2H, –OCH2O–), 6.83 (d, J= 8.4 Hz,
1H, Ar–H10), 6.90 (s, 2H, Ar
0–H5,6), 6.98 (s, 1H, Ar0–H2),
7.39 (d, J= 6.9 Hz, 1H, Ar–H3), 7.49 (t, J= 7.8 Hz, 1H,
Ar–H9), 7.64 (t, J= 7.8 Hz, 1H, Ar–H4), 7.79 (d,
J= 7.2 Hz, 1H, Ar–H8), 7.87 (d, J= 8.1 Hz, 1H, Ar–H5),
10.31 (t, J= 5.4 Hz, 1H, –NH–), 13.60 (br, 1H, pyrazole-
NH). 13C NMR (75 MHz, DMSO-d6): d (ppm) 46.32,
101.44, 108.36, 108.82, 109.81, 112.81, 114.60, 116.47, 119.74,
121.09, 122.14, 127.12, 129.03, 129.19, 133.21, 133.63, 135.64,
146.99, 148.15, 153.53, 187.23 (C‚O). HRMS (EI) m/z calcd
for C22H15N3O3
+ [M]+: 369.1113, found, 369.1107.
2.3.17. 7-Chloro-2-(2-hydroxyethyl)anthra[1,9-cd]pyrazol-
6(2H)-one (17)
The pure compound was obtained as a yellow solid (yield
37%). (Rf = 0.26 at ethyl acetate:n-hexane = 6:1). Mp 185–
186 C (EtOH) (Zhang et al., 2010). FT-IR (KBr; m cm1):
3481 (OH), 1622 (C‚O), 1600 (C‚N). 1H NMR (300 MHz,
DMSO-d6): d (ppm) 3.87–3.93 (m, 2H, –NCH2–), 4.63 (t,
J= 5.1 Hz, 2H, –OCH2–), 4.95 (t, J= 5.7 Hz, 1H, –OH),
7.60 (dd, J= 7.8, 1.2 Hz, 1H, Ar–H10), 7.72 (t, J= 8.1 Hz,
1H, Ar–H4), 7.73 (t, J= 7.2 Hz, 1H, Ar–H9), 7.89 (d,
J= 6.9 Hz, 1H, Ar–H3), 8.09 (d, J= 7.8 Hz, 1H, Ar–H8),
8.17 (dd, J= 7.8, 1.5 Hz, 1H, Ar–H5).
13C NMR (75 MHz,
DMSO-d6): d (ppm) 53.00, 60.75, 117.34, 120.92, 122.23,
126.29, 128.77, 129.03, 132.69, 134.30, 134.92, 136.29, 137.33,
140.21, 182.10 (C‚O). HRMS (EI) m/z calcd for
C16H11ClN2O2
+ [M]+: 298.0509, found, 267.0325 (100),
298.0513 (35), 300.0498 (10).
2.3.18. (7-[2-(Methyl)propylamino]-2-(2-
hydroxyethyl)anthra[1,9-cd]pyrazol-6(2H)-one (18)
Product 18 was prepared from 17 with isobutylamine. The red
solid material was isolated in 46% yield (Rf = 0.41 at ethyl
acetate:n-hexane = 6:1). Mp 134–135 C (EtOH). FT-IR
(KBr; m cm1): 3423 (OH), 1618 (C‚O), 1596 (C‚N). 1H
NMR (300 MHz, DMSO-d6): d (ppm) 1.03 (t, J= 6.6 Hz,
6H, –CH3), 1.93–2.02 (m, 1H, –CH–), 3.12 (t, J= 5.4 Hz,
2H, –NCH2–), 3.88 (m, 2H, –NCH2–), 4.57 (t, J= 5.4 Hz,
2H, –OCH2–), 4.94 (t, J= 5.4 Hz, 1H, –OH), 6.82 (d,
J= 8.1 Hz, 1H, Ar–H10), 7.30 (d, J= 7.2 Hz, 1H, Ar–H3),
7.49 (t, J= 8.0 Hz, 1H, Ar–H9), 7.63 (t, J= 7.5 Hz, 1H,
Ar–H4), 7.78 (d, J= 6.9 Hz, 1H, Ar–H8), 7.93 (d,
J= 8.1 Hz, 1H, Ar–H5), 10.17 (t, J= 5.1 Hz, 1H, –NH).
13C NMR (75 MHz, DMSO-d6): d (ppm) 20.40, 27.79, 50.13,
52.71, 60.66, 109.10, 112.24, 113.93, 116.21, 119.53, 122.46,
127.05, 128.55, 133.18, 135.46, 139.01, 139.85, 153.99, 186.71
(C‚O). HRMS (EI) m/z calcd for C20H21N3O2
+ [M]+:
335.1643, found, 292.1081 (100), 335.1628 (30).Please cite this article in press as: Chen, T.-C. et al., Synthesis and biological evaluatio
agents. Arabian Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.20152.3.19. 7-Propylamino-2-(2-hydroxyethyl)anthra[1,9-
cd]pyrazol-6(2H)-one (19)
Product 19 was prepared from 17 with propylamine. The red
solid material was isolated in 71% yield (Rf = 0.41 at ethyl
acetate:n-hexane = 6:1). Mp 181–182 C (EtOH). FT-IR
(KBr; m cm1): 3282 (OH), 1616 (C‚O), 1595 (C‚N). 1H
NMR (300 MHz, Acetone-d6): d (ppm) 1.10 (t, J= 7.5 Hz,
3H, –CH3), 1.79 (p, J= 7.2 Hz, 2H, –CH2–), 3.32 (q,
J= 6.9 Hz, 2H, –NCH2–), 4.09 (t, J= 6.9 Hz, 2H, –NCH2–
), 4.65 (t, J= 5.1 Hz, 2H, –OCH2–), 6.86 (d, J= 8.4 Hz,
1H, Ar–H10), 7.40 (dd, J= 7.5, 1.2 Hz, 1H, Ar–H3), 7.51 (t,
J= 7.8 Hz, 1H, Ar–H9), 7.64 (t, J= 7.5 Hz, 1H, Ar–H4),
7.83 (d, J= 7.2 Hz, 1H, Ar–H8), 7.90 (d, J= 8.1 Hz, 1H,
Ar–H5), 10.16 (br, 1H, –NH).
13C NMR (75 MHz, DMSO-
d6): d (ppm) 11.78, 22.16, 44.20, 52.77, 60.78, 109.19, 112.25,
113.91, 116.31, 119.58, 122.49, 127.09, 128.64, 133.23, 135.56,
139.06, 139.91, 153.86, 186.71 (C‚O). HRMS (EI) m/z calcd
for C19H19N3O2




Product 20 was prepared from 17 with 5-amino-1-pentanol.
The red solid material was isolated in 48% yield (Rf = 0.18
at ethyl acetate:n-hexane = 6:1). Mp 183–184 C (EtOH).
FT-IR (KBr; m cm1): 3361 (OH), 1614 (C‚O), 1595
(C‚N). 1H NMR (300 MHz, Acetone-d6): d (ppm) 1.61–
1.63 (m, 4H, –CH2–), 1.77–1.84 (m, 2H, –CH2–), 3.34–3.40
(m, 2H, –NCH2–), 3.46 (t, J= 5.1 Hz, 1H, –OH), 3.60 (t,
J= 5.4 Hz, 2H, –NCH2–), 4.09 (t, J= 4.8 Hz, 2H, –OCH2–
), 4.65 (t, J= 5.1 Hz, 2H, –OCH2–), 6.86 (d, J= 8.4 Hz,
1H, Ar–H10), 7.40 (dd, J= 6.3, 1.2 Hz, 1H, Ar–H3), 7.51 (t,
J= 8.1 Hz, 1H, Ar–H9), 7.64 (t, J= 7.8 Hz, 1H, Ar–H4),
7.83 (d, J= 6.9 Hz, 1H, Ar–H8), 7.90 (d, J= 8.4 Hz, 1H,
Ar–H5), 10.16 (br, 1H, –NH).
13C NMR (75 MHz, DMSO-
d6): d (ppm) 23.57, 28.85, 32.52, 42.49, 52.76, 60.75, 61.03,
109.16, 112.23, 113.90, 116.29, 119.57, 122.49, 127.08, 128.63,
133.21, 135.55, 139.05, 139.90, 153.83, 186.68 (C‚O).
HRMS (EI) m/z calcd for C21H23N3O3
+ [M]+: 365.1739,
found, 292.1078 (100), 365.1739 (20).
2.3.21. 7-Phenethylamino-2-(2-hydroxyethyl)anthra[1,9-
cd]pyrazol-6(2H)-one (21)
Product 21 was prepared from 17 with phenethylamine. The
red solid material was isolated in 71% yield (Rf = 0.40 at ethyl
acetate:n-hexane = 6:1). Mp 171–172 C (EtOH). FT-IR
(KBr; m cm1): 3298 (OH), 1618 (C‚O), 1595 (C‚N). 1H
NMR (300 MHz, Acetone-d6): d (ppm) 3.09 (t, J= 7.2 Hz,
2H, –CH2–), 3.59–3.66 (m, 2H, –NCH2–), 4.09 (t,
J= 4.2 Hz, 2H, –NCH2–), 4.08–4.11 (br, 1H, –OH), 4.64 (t,
J= 4.5 Hz, 2H, –OCH2–), 6.92 (d, J= 8.4 Hz, 1H, Ar–
H10), 7.23 (t, J= 8.7 Hz, 2H, Ar
0–H2,6), 7.33 (t, J= 6.9 Hz,
3H, Ar0–H3,4,5), 7.41 (d, J= 7.8 Hz, 1H, Ar–H3), 7.51 (t,
J= 7.8 Hz, 1H, Ar–H9), 7.63 (t, J= 7.5 Hz, 1H, Ar–H4),
7.81 (d, J= 7.2 Hz, 1H, Ar–H8), 7.89 (d, J= 8.1 Hz, 1H,
Ar–H5), 10.21 (br, 1H, –NH).
13C NMR (75 MHz, DMSO-
d6): d (ppm) 35.08, 44.01, 52.77, 60.75, 109.39, 112.29,
114.04, 116.34, 119.62, 122.46, 126.68, 127.00, 128.63, 128.81,
129.16, 133.22, 135.57, 139.01, 139.69, 139.90, 153.56, 186.62n of anthra [1,9-cd]pyrazol-6(2H)-one scaﬀold derivatives as potential anticancer
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8 T.-C. Chen et al.(C‚O). HRMS (EI) m/z calcd for C24H21N3O2
+ [M]+:
383.1634, found, 292.1084 (100), 383.1629 (7).
2.3.22. 7-Cyclohexylamino-2-(2-hydroxyethyl)anthra[1,9-
cd]pyrazol-6(2H)-one (22)
Product 22 was prepared from 17 with cyclohexylamine. The
red solid material was isolated in 52% yield (Rf = 0.43 at ethyl
acetate:n-hexane = 6:1). Mp 217–218 C (EtOH). FT-IR
(KBr; m cm1): 3419 (OH), 1652 (C‚O), 1614 (C‚N). 1H
NMR (300 MHz, DMSO-d6): d (ppm) 1.35–2.01 (m, 10H,
cyclohexyl-CH2), 3.59–3.60 (m, 1H, –NCH–), 3.85–3.91 (m,
2H, –NCH2–), 4.58 (t, J= 5.4 Hz, 2H, –OCH2–), 4.94 (t,
J= 5.4 Hz, 1H, –OH), 6.89 (d, J= 8.4 Hz, 1H, Ar–H10),
7.29 (d, J= 7.2 Hz, 1H, Ar–H3), 7.49 (t, J= 8.1 Hz, 1H,
Ar–H9), 7.64 (t, J= 7.2 Hz, 1H, Ar–H4), 7.77 (d,
J= 7.2 Hz, 1H, Ar–H8), 7.94 (d, J= 8.1 Hz, 1H, Ar–H5),
10.21 (d, J= 4.8 Hz, 1H, –NH). 13C NMR (75 MHz,
DMSO-d6): d (ppm) 24.15, 25.65, 32.58, 49.84, 52.79, 60.78,
109.01, 112.76, 113.81, 116.29, 119.57, 122.49, 127.16, 128.69,
133.38, 135.53, 139.10, 139.91, 152.95, 186.71 (C‚O).
HRMS (EI) m/z calcd for C22H23N3O2
+ [M]+: 361.1790,
found, 318.1241 (100), 361.1794 (75).
2.3.23. 7-Cyclopentylamino-2-(2-hydroxyethyl)anthra[1,9-
cd]pyrazol-6(2H)-one (23)
Product 23 was prepared 17 with cyclopentylamine. The red
solid material was isolated in 42% yield (Rf = 0.38 at ethyl
acetate:n-hexane = 6:1). Mp 198–199 C (EtOH). FT-IR
(KBr; m cm1): 3392 (OH), 1649 (C‚O), 1614 (C‚N). 1H
NMR (300 MHz, DMSO-d6): d (ppm) 1.52–2.11 (m, 8H,
cyclopentane-CH2), 3.85–3.91 (m, 2H, –NCH2–), 3.98–4.03
(m, 1H, cyclopentane-CH), 4.58 (t, J= 5.4 Hz, 2H, –OCH2–
), 4.94 (t, J= 5.4 Hz, 1H, –OH), 6.87 (d, J= 8.4 Hz, 1H,
Ar–H10), 7.30 (d, J= 7.2 Hz, 1H, Ar–H3), 7.51 (t,
J= 8.1 Hz, 1H, Ar–H9), 7.64 (t, J= 7.5 Hz, 1H, Ar–H4),
7.77 (d, J= 7.2 Hz, 1H, Ar–H8), 7.95 (d, J= 8.4 Hz, 1H,
Ar–H5), 10.17 (d, J= 6.0 Hz, 1H, –NH).
13C NMR
(75 MHz, DMSO-d6): d (ppm) 24.02, 33.48, 52.86, 53.54,
60.85, 109.27, 113.19, 113.99, 116.46, 119.73, 122.55, 127.18,
128.83, 133.34, 135.63, 139.14, 140.01, 153.40, 186.79
(C‚O). HRMS (EI) m/z calcd for C21H21N3O2
+ [M]+:
347.1634, found, 318.1250 (80), 347.1624 (100).
2.3.24. 7-Methylcyclohexylamino-2-(2-
hydroxyethyl)anthra[1,9-cd]pyrazol-6(2H)-one (24)
Product 24 was prepared from 17 with aminomethylcyclohex-
ane. The red solid material was isolated in 54% yield
(Rf = 0.41 at ethyl acetate:n-hexane = 6:1). Mp 163–164 C
(EtOH). FT-IR (KBr; m cm1): 3444 (OH), 1652 (C‚O),
1616 (C‚N). 1H NMR (300 MHz, Acetone-d6): d (ppm)
1.08–1.93 (m, 10H, cyclohexane-CH2), 1.99 (br, 1H,
cyclohexane-CH), 3.20 (t, J= 5.7 Hz, 2H, –NCH2–), 4.06–
4.16 (m, 2H, –NCH2–), 4.06–4.16 (m, 1H, –OH), 4.64 (t,
J= 5.1 Hz, 2H, –OCH2–), 6.85 (d, J= 8.7 Hz, 1H, Ar–
H10), 7.39 (dd, J= 7.2, 1.2 Hz, 1H, Ar–H3), 7.48 (t,
J= 8.1 Hz, 1H, Ar–H9), 7.63 (t, J= 7.5 Hz, 1H, Ar–H4),
7.82 (d, J= 7.2 Hz, 1H, Ar–H8), 7.88 (d, J= 8.4 Hz, 1H,
Ar–H5), 10.21 (br, 1H, –NH).
13C NMR (75 MHz, DMSO-
d6): d (ppm) 25.72, 26.31, 30.92, 37.33, 48.90, 52.77, 60.74,
109.10, 112.31, 113.91, 116.34, 119.61, 122.49, 127.09, 128.65,Please cite this article in press as: Chen, T.-C. et al., Synthesis and biological evaluatio
agents. Arabian Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.2015133.23, 135.57, 139.04, 139.90, 154.02, 186.74 (C‚O).
HRMS (EI) m/z calcd for C23H25N3O2
+ [M]+: 375.1947,
found, 292.1080 (100), 375.1937 (25).
2.3.25. 7-[3-(Hydroxyl)propylamino]-2-(2-
hydroxyethyl)anthra[1,9-cd]pyrazol-6(2H)-one (25)
Product 25 was prepared from 17 with 3-amino-1-propanol.
The red solid material was isolated in 75% yield (Rf = 0.18
at ethyl acetate:n-hexane = 6:1). Mp 208–209 C (EtOH).
FT-IR (KBr; m cm1): 3354 (OH), 1652 (C‚O), 1614
(C‚N). 1H NMR (300 MHz, Acetone-d6): d (ppm) 1.95–
2.00 (m, 2H, –CH2–), 3.44–3.51 (m, 2H, –CH2–), 3.77 (t,
J= 5.1 Hz, 2H, –NCH2–), 4.09 (t, J= 4.8 Hz, 2H, –NCH2–
), 4.08–4.11 (br, 1H, –OH), 4.65 (t, J= 4.8 Hz, 2H, –OCH2–
), 6.90 (d, J= 7.8 Hz, 1H, Ar–H10), 7.41 (d, J= 7.2, 1.2 Hz,
1H, Ar–H3), 7.52 (t, J= 8.7 Hz, 1H, Ar–H9), 7.65 (t,
J= 8.1 Hz, 1H, Ar–H4), 7.83 (d, J= 7.2 Hz, 1H, Ar–H8),
7.91 (d, J= 8.1 Hz, 1H, Ar–H5), 10.19 (br, 1H, –NH).
13C
NMR (75 MHz, DMSO-d6): d (ppm) 32.28, 39.54, 52.77,
58.81, 60.80, 109.18, 112.19, 113.97, 116.22, 119.53, 122.49,
127.10, 128.61, 133.21, 135.50, 139.08, 139.88, 153.85, 186.62
(C‚O). HRMS (EI) m/z calcd for C19H19N3O3
+ [M]+:
337.1426, found, 292.1097 (100), 337.1432 (25).
2.3.26. 7-Butylamino-2-(2-hydroxyethyl)anthra[1,9-
cd]pyrazol-6(2H)-one (26)
Compound 26 was prepared from 17 with butylamine. The
pure product was obtained as red powder (yield 58%)
(Rf = 0.45 at ethyl acetate:hexane = 6:1). Mp 279–281 C
(EtOH). FT-IR (KBr; m cm1): 3319 (OH), 1649 (C‚O),
1618 (C‚N). 1H NMR (300 MHz, DMSO-d6): d (ppm) 1.02
(t, J= 7.2 Hz, 3H, –CH3), 1.52–1.62 (m, 2H, –CH2–), 1.72–
1.82 (m, 2H, –CH2–), 3.32–3.81 (m, 2H, –CH2–), 4.06–4.16
(br, 3H, –NCH2– & –OH), 4.64 (t, J= 5.1 Hz, 2H, –OCH2–
), 6.85 (d, J= 8.7 Hz, 1H, Ar–H10), 7.39 (dd, J= 7.2,
1.2 Hz, 1H, Ar–H3), 7.49 (t, J= 8.1 Hz, 1H, Ar–H9), 7.63 (t,
J= 7.5 Hz, 1H, Ar–H4), 7.81 (d, J= 6.9 Hz, 1H, Ar–H8),
7.88 (d, J= 8.1 Hz, 1H, Ar–H5), 10.13 (br, 1H, pyrazole-
NH). 13C NMR (75 MHz, Acetone-d6): d (ppm) 13.89, 20.09,
31.01, 42.11, 52.77, 60.77, 109.17, 112.22, 113.91, 116.28,
119.56, 122.49, 127.09, 128.62, 133.22, 135.54, 139.06, 139.89,
153.83, 186.69 (C‚O). HRMS (EI) m/z calcd for
C20H21N3O2




Compound 27 was prepared from 17 with methylamine. The
pure product was obtained as red powder (yield 16%)
(Rf = 0.24 at ethyl acetate:n-hexane = 3:2). Mp 213–214 C
(EtOH). FT-IR (KBr; m cm1): 3265 (OH), 1649 (C‚O),
1620 (C‚N). 1H NMR (300 MHz, Acetone-d6): d (ppm)
3.04 (d, J= 4.8 Hz, 3H, –CH3), 4.11 (m, 3H, –NCH2– & –
OH), 4.66 (t, J= 4.5 Hz, 2H, –OCH2–), 6.84 (d, J= 8.7 Hz,
1H, Ar–H10), 7.42 (d, J= 7.5 Hz, 1H, Ar–H3), 7.54 (t,
J= 7.5 Hz, 1H, Ar–H9), 7.65 (t, J= 7.2 Hz, 1H, Ar–H4),
7.83 (d, J= 7.2 Hz, 1H, Ar–H8), 7.92 (d, J= 8.1 Hz, 1H,
Ar–H5), 10.00 (br, 1H, –NH).
13C NMR (75 MHz, DMSO-
d6): d (ppm) 29.47, 52.78, 60.76, 109.22, 111.93, 114.12,
116.37, 119.57, 122.51, 127.06, 128.67, 133.17, 135.61, 139.07,
139.94, 154.59, 186.59 (C‚O). HRMS (EI) m/z calcd forn of anthra [1,9-cd]pyrazol-6(2H)-one scaﬀold derivatives as potential anticancer
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Synthesis and biological evaluation of anthra[1,9-cd]pyrazol-6(2H)-one scaffold derivatives 9C17H15N3O2
+ [M]+: 293.1164, found 233.0775 (20), 244.0928
(35), 262.1017 (30), 276.1142 (20), 293.1160 (100).
2.3.28. 7-Benzylamino-2-(2-hydroxyethyl)anthra[1,9-
cd]pyrazol-6(2H)-one (28)
Compound 28 was prepared from 17 with benzylamine. The
pure product was obtained as red powder (yield 54%)
(Rf = 0.24 at ethyl acetate:n-hexane = 3:2). Mp 163–165 C
(EtOH). FT-IR (KBr; m cm1): 3309 (OH), 1652 (C‚O),
1620 (C‚N). 1H NMR (300 MHz, Acetone-d6): d (ppm)
4.08–4.11 (m, 2H, –NCH2–), 4.08–4.11 (m, 1H, –OH), 4.65
(m, 4H, –CH2–), 6.85 (dd, J= 7.8, 2.1 Hz, 1H, Ar–H10),
7.30 (t, J= 7.2 Hz, 1H, Ar0–H4), 7.39 (t, J= 7.2 Hz, 2H,
Ar0–H3,5), 7.48 (d, J= 6.3 Hz, 2H, Ar0–H2,6), 7.48 (d,
J= 6.3 Hz, 1H, Ar–H3), 7.49 (t, J= 7.5 Hz, 1H, Ar–H9),
7.66 (t, J= 7.8 Hz, 1H, Ar–H4), 7.85 (d, J= 2.1 Hz, 1H,
Ar–H8), 7.88 (d, J= 3.0 Hz, 1H, Ar–H5), 10.54 (br, 1H, –
NH). 13C NMR (75 MHz, DMSO-d6): d (ppm) 46.42, 52.80,
60.75, 109.70, 112.65, 114.38, 116.49, 119.73, 122.49, 126.97,
127.56, 127.73, 128.67, 129.06, 133.28, 135.52, 138.96, 139.29,
139.93, 153.53, 186.86 (C‚O). HRMS (EI) m/z calcd for
C17H15N3O2




Compound 29 was prepared from 17 with 2-(1-
cyclohexenyl)ethylamine. The pure product was obtained as
red powder (yield 62%) (Rf = 0.48 at ethyl acetate:hex-
ane = 6:1). Mp 151–152 C (EtOH). FT-IR (KBr; m cm1):
3446 (OH), 1652 (C‚O), 1614 (C‚N). 1H NMR (300 MHz,
Acetone-d6): d (ppm) 1.54–1.69 (m, 8H, cyclohexene-CH2),
2.40 (t, J= 6.6 Hz, 2H, –CH2–), 3.42 (dd, J= 13.8, 5.1 Hz,
2H, –CH2–), 4.08 (t, J= 5.1 Hz, 2H, –NCH2–), 4.04–4.10
(br, 1H, –OH), 4.64 (t, J= 5.4 Hz, 2H, –OCH2–), 5.66 (br,
1H, cyclohexene-CH), 6.84 (dd, J= 8.7, 0.9 Hz, 1H, Ar–
H10), 7.38 (dd, J= 7.5, 1.5 Hz, 1H, Ar–H3), 7.49 (t,
J= 8.1 Hz, 1H, Ar–H9), 7.61 (t, J= 7.8 Hz, 1H, Ar–H4),
7.79 (d, J= 6.9 Hz, 1H, Ar–H8), 7.87 (d, J= 8.1 Hz, 1H,
Ar–H5), 10.13 (br, 1H, –NH–).
13C NMR (75 MHz, DMSO-
d6): d (ppm) 22.26, 22.76, 25.10, 27.88, 37.19, 41.04, 52.76,
60.80, 109.24, 112.35, 114.06, 116.22, 119.55, 122.51, 123.46,
127.10, 128.61, 133.21, 135.04, 135.47, 139.10, 139.90, 153.65,
186.57 (C‚O). HRMS (EI) m/z calcd for C24H25N3O2
+
[M]+: 387.1947, found, 292.1094 (100), 387.1945 (5).
2.3.30. 7-[2-(4-Methoxyphenyl)ethylamino]-2-(2-
hydroxyethyl)anthra[1,9-cd]pyrazol-6(2H)-one (30)
Compound 30 was prepared from 17 with 2-(4-
methoxyphenyl)ethylamine. The pure product was recrystal-
lized from ethanol to get the red powder (yield 48%)
(Rf = 0.35 at ethyl acetate:n-hexane = 6:1). Mp 151–152 C
(EtOH). FT-IR (KBr; m cm1): 3502 (OH), 1650 (C‚O),
1616 (C‚N). 1H NMR (300 MHz, Acetone-d6): d (ppm)
3.02 (t, J= 7.2 Hz, 2H, –CH2–), 3.54–3.61 (m, 2H, –NCH2–
), 3.71 (s, 3H, –OCH3), 4.07–4.90 (m, 2H, –NCH2– & –OH),
4.65 (t, J= 5.1 Hz, 2H, –OCH2–), 6.90 (d, J= 6.9 Hz, 4H,
Ar0–H), 7.32 (d, J= 8.4 Hz, 1H, Ar–H10), 7.38 (dd, J= 7.2,
1.2 Hz, 1H, Ar–H3), 7.51 (t, J= 7.5 Hz, 1H, Ar–H9), 7.63 (t,
J= 7.5 Hz, 1H, Ar–H4), 7.81 (d, J= 6.9 Hz, 1H, Ar–H8),
7.89 (d, J= 8.1 Hz, 1H, Ar–H5), 10.18 (br, 1H, –NH–).
13CPlease cite this article in press as: Chen, T.-C. et al., Synthesis and biological evaluatio
agents. Arabian Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.2015NMR (75 MHz, DMSO-d6): d (ppm) 34.21, 44.27, 52.77,
55.39, 60.77, 109.36, 112.29, 114.03, 114.37, 116.31, 119.62,
122.48, 127.04, 128.63, 130.13, 131.57, 133.22, 135.56, 139.04,
139.91, 153.57, 158.42, 186.62 (C‚O). HRMS (EI) m/z calcd
for C25H23N3O3




Compound 31 was prepared from 17 with 2-
methoxybenzylamine. The pure product was recrystallized
from dichloromethane and hexane to get the red powder (yield
54%) (Rf = 0.35 at ethyl acetate:hexane = 6:1). Mp 181–
182 C. FT-IR (KBr; m cm1): 3419 (OH), 1652 (C‚O),
1618 (C‚N). 1H NMR (300 MHz, Acetone-d6): d (ppm)
3.93 (s, 3H, –OCH3), 4.08–4.11 (m, 2H, –NCH2– & –OH),
4.59 (d, J= 6.0 Hz, 2H, –NCH2–), 4.65 (t, J= 5.1 Hz, 2H,
–OCH2–), 6.85 (dd, J= 8.1, 1.5 Hz, 1H, Ar–H10), 6.94 (t,
J= 7.2 Hz, 1H, Ar0–H5), 7.06 (d, J= 7.8 Hz, 1H, Ar–H3),
7.29 (t, J= 7.2 Hz, 1H, Ar–H9), 7.37 (d, J= 7.2 Hz, 1H,
Ar0–H3), 7.41 (dd, J= 7.5, 1.5 Hz, 1H, Ar0–H6), 7.47 (t,
J= 7.8 Hz, 1H, Ar0–H4), 7.64 (t, J= 7.8 Hz, 1H, Ar–H4),
7.83 (d, J= 7.2 Hz, 1H, Ar–H8), 7.90 (d, J= 8.1 Hz, 1H,
Ar–H5), 10.48 (br, 1H, –NH–).
13C NMR (75 MHz, DMSO-
d6): d (ppm) 41.51, 52.77, 55.87, 60.75, 109.47, 111.53,
112.46, 114.30, 116.39, 119.66, 120.85, 122.49, 126.68, 127.02,
128.64, 128.80, 129.01, 133.27, 135.51, 139.00, 139.91, 153.63,
157.66, 186.72 (C‚O). HRMS (EI) m/z calcd for
C24H21N3O3




Compound 32 was prepared from 17 with piperonylamine.
The pure product was obtained as red powder (yield 43%)
(Rf = 0.35 at ethyl acetate:hexane = 6:1). Mp 219–220 C.
FT-IR (KBr; m cm1): 3273 (OH), 1616 (C‚O), 1593
(C‚N). 1H NMR (300 MHz, DMSO-d6): d (ppm) 3.88 (q,
J= 5.1 Hz, 2H, –CH2–), 4.45 (d, J= 5.4 Hz, 2H, –CH2–),
4.58 (t, J= 5.7 Hz, 2H, –CH2–), 4.94 (t, J= 5.4 Hz,
1H, –OH), 6.00 (s, 2H, –OCH2O–), 6.83 (d, J= 8.1 Hz, 1H,
Ar–H10), 6.90 (d, J= 0.9 Hz, 2H, Ar
0–H5,6), 6.98 (s, 1H,
Ar0–H2), 7.33 (dd, J= 7.2, 1.2 Hz, 1H, Ar–H3), 7.49 (t,
J= 8.7 Hz, 1H, Ar–H9), 7.65 (t, J= 7.5 Hz, 1H, Ar–H4),
7.78 (d, J= 6.9 Hz, 1H, Ar–H8), 7.96 (d, J= 8.1 Hz, 1H,
Ar–H5), 10.31 (t, J= 5.7 Hz, 1H, –NH–).
13C NMR
(75 MHz, DMSO-d6): d (ppm) 46.26, 52.83, 60.80, 101.39,
108.33, 108.77, 109.75, 112.73, 114.39, 116.54, 119.79, 121.05,
122.53, 127.03, 128.75, 133.13, 133.29, 135.58, 139.01, 139.97,
146.93, 148.10, 153.48, 186.88 (C‚O). HRMS (EI) m/z calcd
for C24H19N3O4
+ [M]+: 413.1376, found, 413.1375.
2.4. Sulforhodamine B assay
Sulforhodamine B was obtained from Sigma–Aldrich Corp.
(St. Louis, MO, USA). Human hormone-refractory prostate
cancer cell line PC-3 was from American Type Culture
Collection (ATCC) (Rockville, MD). The cells were cultured
in RPMI1640 medium with penicillin (100
units/mL)/streptomycin (0.1 mg/mL) and 5% fetal bovine
serum (FBS) (v/v). Cultures were maintained in a humidiﬁedn of anthra [1,9-cd]pyrazol-6(2H)-one scaﬀold derivatives as potential anticancer
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Table 1 50% cell toxicity concentration of anthra[1,9-
cd]pyrazol-6(2H)-one derivatives against PC-3 cell line in
SRB assay.
Compound IC50 (lM) Compound IC50 (lM)
1 18.10 17 13.70
2 17.83 18 28.51
3 >30 19 >30
4 9.99 20 >30
5 21.87 21 >30
6 12.85 22 >30
7 15.84 23 22.17
8 20.05 24 17.96
9 14.47 25 18.69
10 24.30 26 >30
11 >30 27 >30
12 8.63 28 >30
13 >30 29 21.09
14 >30 30 >30
15 8.44 31 >30
16 5.49 32 >30
SP600125 N.D. Mitoxantrone 0.29
10 T.-C. Chen et al.incubator at 37 C in 95% air and 5% CO2. About 5 · 103 cells
were seeded in 96-well plates in medium with 5% FBS. After
24 h, PC-3 cells were ﬁxed with 10% trichloroacetic acid
(TCA) to represent cell population at the time of compound
addition (T0). After additional incubation of vehicle (0.1%
DMSO) or the indicated compound for 48 h, cells were ﬁxed
with 10% TCA and SRB at 0.4% (w/v) in 1% acetic acid
was added to stain cells. Unbound SRB was washed out by
1% acetic acid and SRB bound cells were solubilized with
0.01 M Trizma base. The absorbance was detected at a wave-
length of 515 nm by spectrophotometer. Using the following
absorbance measurements, such as time zero (T0), control
growth (C), and cell growth in the presence of compound
(Tx), the percentage growth was calculated at each of the com-
pound concentrations levels. Percentage growth inhibition was
calculated as: 100  [(Tx  T0)/(C  T0)] · 100 for concentra-
tions for which TxP T0. The value of GI50 was determined
at the drug concentration which results in 50% reduction of
total protein increase in control cells during the compound
incubation.
2.5. Telomeric repeat ampliﬁcation protocol (TRAP) assays
The activity of telomerase was investigated by a modiﬁed ver-
sion of the telomeric repeat ampliﬁcation protocol (TRAP)
protocol (Kim et al., 1994; Huang et al., 2008). Telomerase
products were resolved by 10% polyacrylamide gel elec-
trophoresis and visualized by staining with SYBER Green.
As a source of telomerase, the total cell lysates derived from
lung cancer cell line H1299 cells were used. Bovine serum albu-
min (BSA) was used as a standard to quantify protein.
According to the BSA standard curve, the protein concentra-
tion of the lysates was assayed using Bio-Rad protein assay kit.
3. Biological evaluation
All of the synthesized compounds (1–32) were tested against
PC-3 cell line by sulforhodamine B (SRB) assay.
Simultaneously, the effects of compounds (1–32) for the inhi-
bitory of telomerase by TRAP assay were also evaluated
(Kim et al., 1994; Huang et al., 2008). Moreover, ﬁfteen of
our structures (1–6, 13, 14, 16, 17, 19, 21, 23, 28 and 31) were
selected by NCI to be investigated against a panel of 60 human
cancer cell lines. After a primary screening, compounds 1, 4
and 16 were chosen for further cell growth inhibition screening
for the 50% growth inhibitory concentration (GI50), the total
growth inhibition (TGI), and the 50% lethal concentration
(LC50) by NCI.
3.1. Cytotoxicity evaluation
Cell survival rate or proliferation was determined by a com-
mon method, SRB assay. PC-3 cell line was used to evaluate
the cell toxicity of each compound. Untreated cell was used
as the control group, while compound-treated cell was used
as the test group. All of the synthesized compounds were inves-
tigated and the values of IC50 were described as Table 1.
Compounds with linear alkanes as side chain were exhibited
the worse activities than others. Such as compounds 3/19
and 11/27, the IC50 values were higher than 30 lM. It isPlease cite this article in press as: Chen, T.-C. et al., Synthesis and biological evaluatio
agents. Arabian Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.2015interesting about compounds 4, 12, 15, and 16 where the values
of IC50 were less than 10 lM.
3.2. In vitro antiproliferative activity
The 7-substituted anthra[1,9-cd]pyrazol-6(2H)-one homo-
logues were investigated for antiproliferative activity against
human tumor cell lines in NCI Drug Screen Program. The
tumor growth inhibition properties of the ﬁfteen compounds
1, 2, 3, 4, 5, 6, 13, 14, 16, 17, 19, 21, 23, 28 and 31 with the
NCI codes NSC764641, 764630, 764631, 764632, 764633,
764634, 764635, 764636, 764637, 764642, 764625, 764626,
764627, 764628 and 764629 (Fig. 2) selected among all submit-
ted compounds were screened on human cancer cell lines at a
primary single concentration (10 lM) at the NIH, Bethesda,
Maryland, USA, under the drug discovery program of the
NCI. The selected compounds were evaluated in NCI’s nine
types of neoplastic cell lines and incubated for 48 h. And each
subpanel has several neoplastic cell lines. The anticancer assay
was executed in light of the protocol of developmental thera-
peutics program (one dose mean graph). Results of selected
synthetic compounds were reported as the growth percent
value of the treated cells (experimental group) when compared
with that of the untreated cells (control group). The growth
percentages at 10 lM for NCI 60 cancer cell lines are described
in Table 2.n of anthra [1,9-cd]pyrazol-6(2H)-one scaﬀold derivatives as potential anticancer
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Figure 2 Selected compounds for testing in the NCI screens.
Synthesis and biological evaluation of anthra[1,9-cd]pyrazol-6(2H)-one scaffold derivatives 113.3. Telomerase inhibitory activities
Telomerase activity plays an important role of cell prolifera-
tion. In our previous studies, we pay attention to the potency
of the synthetic derivatives against telomerase activities in the
cell free extracts of H1299 cells. We evaluated the effects of the
synthetic compounds on telomerase inhibition by TRAP assay.
In the TRAP assay, if a compound can stabilize the telomeric
sequences such that telomerase cannot act on telomere, then
the effect of inhibiting the telomerase can be achieved.
DMSO treatment represents as the positive control group
(P), while a negative control group (N) used 5 lL of
100 lg/mL RNase A (CLONTECH) in the assay. It could be
observed that a number of telomeric fragments were detected
in the positive control group (P), while none was detected inPlease cite this article in press as: Chen, T.-C. et al., Synthesis and biological evaluatio
agents. Arabian Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.2015the negative control group (N). 10 lM was selected as the con-
centration used to screen compounds.
4. Results and discussion
The reaction of 1,5-dichloroanthraquinone and hydrazine
monohydrate was stirred at 120 C in dimethyl sulfoxide
(DMSO) and used N,N-diisopropylethylamine (DIPEA) as a
basic catalyst for 2 h to obtain the key intermediate 1.
Compound 17 is another key intermediate which was obtained
from 1,5-dichloroanthraquinone, 2-hydroxyethylhydrazine
and pyridine under the same condition. The reaction of appro-
priate primary amines with 1 or 17 in DMSO was stirred at
120 C for 4 h and gained the corresponding 7-substituted
anthra[1,9-cd]pyrazol-6(2H)-one (2–16) or 7-substitutedn of anthra [1,9-cd]pyrazol-6(2H)-one scaﬀold derivatives as potential anticancer
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Table 2 Cytotoxicity of selected compounds on 60 human cancer cell lines.
Panel/Cell line Compounds/Growth percent (%)a
Compd. No. 1 2 3 4 5 6 13 14 16 17 19 21 23 28 31
NCI No. NSC764641 NSC764630 NSC764631 NSC764632 NSC764633 NSC764634 NSC764635 NSC764636 NSC764637 NSC764642 NSC764625 NSC764626 NSC764627 NSC764628 NSC764629
Leukemia
CCRF-CEM 72.25 69.66 77.17 38.99 50.81 69.02 83.68 95.35 10.17 90.58 93.22 89.87 69.41 92.80 80.93
HL-60(TB) 64.34 87.69 77.93 38.88 69.81 92.25 90.36 96.19 46.10 96.18 102.79 98.95 71.58 101.09 91.91
K-562 60.92 80.19 79.91 47.34 69.93 64.66 94.72 93.14 48.87 83.40 95.59 88.19 33.24 73.94 50.06
MOLT-4 43.42 55.89 64.13 18.61 48.82 60.33 88.72 80.18 33.14 77.04 94.56 81.97 71.19 87.22 88.99
RPMI-8226 71.57 77.12 86.31 33.11 82.55 66.41 113.59 90.33 38.17 84.67 91.36 96.99 58.44 95.08 86.81
SR 45.92 69.67 67.94 17.73 62.97 55.34 85.91 76.95 3.65 65.84 78.75 78.79 74.70 64.40 39.24
Non-small cell lung cancer
A549/ATCC 52.33 90.46 80.32 48.31 58.41 76.21 90.63 84.45 17.90 86.72 90.38 95.83 82.33 93.54 89.26
EKVX N.T.b N.T. N.T. N.T. N.T. N.T. N.T. N.T. N.T. N.T. N.T. N.T. N.T. N.T. N.T.
HOP-62 80.31 95.56 93.62 75.27 91.46 85.59 106.94 97.61 42.48 81.08 94.20 103.30 98.88 96.45 84.77
HOP-92 71.18 68.14 69.27 30.65 73.24 71.31 105.09 101.06 58.85 84.53 64.09 85.26 60.17 76.63 81.80
NCI-H226 55.98 70.79 68.72 50.07 77.88 73.32 101.95 91.47 50.65 84.76 96.27 100.24 103.60 90.18 90.46
NCI-H23 65.41 80.11 72.41 61.77 83.86 N.T. 101.41 97.47 49.82 N.T. 86.16 N.T. 88.34 86.57 84.17
NCI-H322M 35.74 50.30 38.33 26.56 52.66 52.43 108.29 69.08 26.79 99.99 80.21 93.11 79.74 94.81 99.75
NCI-H460 49.95 77.69 69.52 44.19 68.22 73.29 106.09 97.48 12.78 91.80 104.90 106.44 91.74 109.85 104.05
NCI-H522 87.21 52.57 65.10 29.89 105.42 76.29 89.05 75.02 33.13 66.91 125.19 83.99 79.75 73.93 47.86
Colon cancer
COLO 205 81.44 97.98 103.19 57.19 95.32 109.19 131.78 125.12 30.20 103.62 115.23 108.30 122.92 116.31 106.58
HCC-2998 71.16 108.70 91.33 51.08 84.82 100.42 126.36 117.28 82.41 108.75 108.06 118.43 105.58 106.62 97.53
HCT-116 47.10 68.36 68.42 31.53 51.51 74.44 102.62 96.34 2.72 69.77 73.87 98.77 88.67 85.21 78.36
HCT-15 41.22 59.46 52.34 28.53 51.55 49.99 80.66 79.40 25.11 77.50 90.12 84.36 61.74 77.59 67.16
HT29 69.39 72.99 78.69 44.13 72.31 67.23 90.01 99.40 56.29 81.60 102.62 91.38 62.63 108.53 95.72
KM12 14.94 17.68 14.32 12.27 19.72 24.04 45.94 38.96 7.38 93.13 98.28 88.44 56.26 80.85 62.93
SW-620 63.57 83.61 80.67 45.29 67.02 85.62 114.80 110.14 30.53 80.26 99.26 107.11 110.89 108.30 91.88
CNS cancer
SF-268 65.07 70.79 66.92 44.22 81.16 84.34 99.94 95.89 44.88 99.92 97.41 112.17 87.04 98.08 96.21
SF-295 64.49 N.T. 98.80 41.04 67.97 79.06 94.31 97.94 42.56 80.19 80.18 91.93 83.96 95.34 79.77
SF-539 68.94 82.10 73.48 49.85 70.18 83.73 111.58 87.65 50.65 78.46 88.23 93.71 79.25 85.44 85.77
SNB-19 69.04 76.12 81.20 76.70 112.41 81.58 108.66 117.68 100.12 68.72 97.48 101.70 107.86 98.59 104.59
SNB-75 N.T. N.T. N.T. N.T. N.T. N.T. N.T. N.T. N.T. N.T. N.T. N.T. N.T. N.T. N.T.
U251 50.57 81.87 68.65 46.95 65.74 69.86 94.20 102.40 47.35 78.89 90.22 93.27 84.90 92.71 94.34
Melanoma
LOX IMVI 46.74 60.49 56.87 35.26 63.53 54.02 95.44 94.76 12.49 65.68 93.25 95.81 68.69 89.94 88.00
MALME-3M 76.88 91.98 84.27 47.42 92.31 90.01 114.64 136.43 47.89 99.26 119.47 38.24 117.84 117.85 93.65
M14 61.17 76.76 69.15 32.70 65.29 76.87 104.93 96.82 32.43 112.09 111.61 96.41 107.26 97.10 88.70
MDA-MB-435 79.19 87.77 87.90 49.40 75.77 93.96 101.32 104.19 29.09 100.25 104.77 104.26 95.20 74.17 37.73
SK-MEL-2 46.42 81.43 76.34 19.69 77.84 87.27 95.15 86.33 10.31 127.18 101.84 105.67 108.46 88.33 86.66
SK-MEL-28 107.22 89.27 103.68 62.00 98.33 99.55 111.78 113.85 48.10 116.68 118.63 108.10 103.12 101.72 88.85
SK-MEL-5 71.84 97.41 99.13 58.22 98.33 91.74 103.10 95.71 36.82 79.74 96.90 96.71 99.11 81.37 93.41
UACC-257 92.84 113.65 107.14 91.19 119.93 105.21 119.81 122.83 81.17 111.04 109.67 120.33 117.00 118.41 99.59
UACC-62 65.64 80.42 77.31 59.19 76.52 80.31 90.89 91.33 59.70 102.26 96.78 88.99 93.71 85.51 78.23
Ovarian cancer
IGROV1 38.56 72.95 56.79 28.99 71.93 63.04 98.92 124.74 42.86 90.68 110.15 110.96 106.75 133.22 91.80
OVCAR-3 83.32 92.19 96.61 75.85 108.16 99.19 107.31 103.36 10.68 116.58 114.22 118.27 107.28 111.75 102.87































































































Panel/Cell line Compounds/Growth percent (%)a
Compd. No. 1 2 3 4 5 6 13 14 16 17 19 21 23 28 31
NCI No. NSC764641 NSC764630 NSC764631 NSC764632 NSC764633 NSC764634 NSC764635 NSC764636 NSC764637 NSC764642 NSC764625 NSC764626 NSC764627 NSC764628 NSC764629
OVCAR-5 75.70 72.53 78.24 53.83 86.41 76.69 97.95 94.39 61.57 101.52 89.66 89.63 81.42 91.11 88.08
OVCAR-8 74.44 79.36 81.21 44.95 90.68 81.38 99.23 94.67 58.26 81.99 91.78 99.25 86.92 93.72 99.52
NCI/ADR-RES 88.31 85.02 85.71 52.27 104.43 80.89 109.11 102.75 60.31 87.66 86.90 99.81 91.37 90.02 82.61
SK-OV-3 40.75 81.11 70.98 12.71 85.74 92.52 124.84 105.21 44.75 96.10 97.40 115.11 108.40 100.74 98.07
Renal cancer
786-O 70.65 98.05 95.79 49.43 102.03 93.17 109.16 108.24 46.54 82.52 100.26 109.34 91.59 104.28 102.84
A498 23.72 47.85 21.97 46.78 81.12 66.82 108.64 96.94 39.52 73.74 104.91 78.80 91.23 86.12 108.92
ACHN 37.56 61.12 49.48 32.24 65.34 53.75 85.00 79.94 5.18 69.30 101.63 100.26 90.02 100.54 93.55
CAKI-1 14.82 61.44 43.54 22.08 54.26 50.21 85.41 81.95 10.20 64.42 90.08 101.74 88.81 106.01 100.36
RXF 393 39.34 45.58 51.99 19.32 57.21 46.50 97.75 92.67 15.19 55.70 96.67 84.71 38.44 76.63 74.41
SN12C 59.11 70.36 69.18 36.27 80.41 69.76 97.18 101.67 45.04 80.23 93.61 103.07 82.64 96.04 97.13
TK-10 40.75 82.27 77.73 40.70 76.94 74.04 106.29 93.91 6.44 54.51 90.16 108.19 99.06 109.57 109.16
UO-31 24.18 30.63 34.36 20.06 58.39 20.02 77.73 117.61 14.35 48.97 90.54 97.36 75.33 94.90 88.47
Prostate cancer
PC-3 71.00 82.65 74.17 51.65 84.22 80.22 102.99 97.07 60.59 103.57 94.65 102.57 96.50 99.14 101.38
DU-145 63.43 55.93 57.60 40.21 64.89 77.60 92.14 93.75 28.00 101.80 110.96 101.76 90.10 97.82 93.81
Breast cancer
MCF7 59.11 45.12 55.76 59.14 51.58 46.79 74.89 64.43 46.67 88.00 111.58 74.15 105.97 30.77 54.58
MDA-MB-231/ATCC 74.83 39.83 62.09 50.57 73.55 51.79 89.96 92.24 22.71 86.56 81.87 85.88 57.52 70.77 79.16
HS 578T 62.55 67.17 73.09 48.99 91.45 73.74 119.20 110.21 56.16 77.35 87.37 105.55 90.28 106.60 97.59
BT-549 64.63 83.10 77.53 44.56 80.51 94.63 113.81 104.30 48.59 98.91 89.08 106.30 95.84 91.94 88.88
T-47D 66.36 53.70 51.52 32.27 73.81 55.39 92.13 80.54 31.08 89.44 87.23 63.96 81.80 81.08 84.12
MDA-MB-468 56.11 28.79 49.69 52.10 36.51 43.93 52.99 50.44 25.53 69.13 97.49 47.43 80.55 15.55 9.29
Mean 60.29 72.42 71.24 43.37 75.19 72.42 72.89 98.98 36.17 86.67 96.96 95.54 87.26 91.19 85.74
Delta 45.47 54.74 56.92 31.10 55.47 54.74 52.87 53.04 51.36 37.70 32.87 57.30 54.02 106.74 76.45
Range 92.40 95.97 92.82 78.92 100.21 95.97 89.17 85.84 115.31 78.21 61.10 82.09 115.31 78.21 61.10
a Data obtained from NCI in vitro 60-cell drug screen program at 10 lM concentration.





































































































































Table 3 In vitro growth inhibitory effect of selected compounds 1 (NSC764641), 4 (NSC764632) and 16 (NSC764637) on the NCI-60 human cancer cell lines.
Panel/Cell line
(lM)


























CCRF-CEM 6.32 11.000 0.954 >100 >100 6.51 23.580 0.883 >100 >100 3.31 13.508 0.336 >100 >100
HL-60(TB) 36.9 >100 >100 51.2 >100 >100 56.4 >100 >100
K-562 7.80 >100 >100 69.6 >100 >100 9.08 >100 >100
MOLT-4 4.41 >100 >100 6.88 >100 >100 6.32 77.9 >100
RPMI-8226 7.48 >100 >100 4.18 >100 >100 3.00 17.3 >100
SR 3.09 >100 >100 3.11 >100 >100 2.94 53.1 >100
Non-small cell lung cancer
A549/ATCC 4.87 6.477 1.621 >100 >100 9.09 12.940 1.610 >100 >100 2.76 3.201 1.419 10.4 78.6
EKVX N.T. N.T. N.T. N.T. N.T. N.T. N.T. N.T. N.T.
HOP-62 12.3 >100 >100 7.00 >100 >100 3.18 8.37 30.7
HOP-92 N.T. N.T. N.T. N.T. N.T. N.T. N.T. N.T. N.T.
NCI-H226 7.77 >100 >100 18.00 >100 >100 2.52 10.4 49.7
NCI-H23 6.65 >100 >100 41.7 >100 >100 4.72 30.2 >100
NCI-H322M 5.62 >100 >100 4.52 >100 >100 3.2 12.8 >100
NCI-460 4.15 >100 >100 6.01 >100 >100 2.52 7.44 >100
NCI-H522 3.98 >100 >100 4.26 >100 >100 3.51 20.9 >100
Colon cancer
COLO 205 12.2 9.763 1.075 >100 >100 18.4 19.830 1.051 >100 >100 2.83 3.517 1.291 6.33 39.8
HCC-2998 30.9 >100 >100 >100 >100 >100 6.77 >100 >100
HCT-116 5.42 >100 >100 3.87 >100 >100 2.19 4.92 14.1
HCT-15 4.34 >100 >100 2.02 >100 >100 3.44 >100 >100
HT29 7.84 >100 >100 7.56 >100 >100 4.61 20.4 >100
KM12 2.50 >100 >100 0.54 >100 >100 0.96 16.6 >100
SW-620 5.14 >100 >100 6.42 >100 >100 3.82 19.7 >100
CNS cancer
SF-268 8.71 8.053 1.304 >100 >100 7.95 28.398 0.734 >100 >100 5.44 4.358 1.042 29.4 >100
SF-295 7.79 >100 >100 6.19 >100 >100 N.T. N.T. N.T.
SF-539 14.2 >100 >100 40.9 >100 >100 3.68 15.7 >100
SNB-19 8.27 >100 >100 >100 >100 >100 7.73 40.1 >100
SNB-75 4.53 >100 >100 4.35 >100 >100 1.89 6.87 81.8
U251 4.82 >100 >100 11.0 >100 >100 3.05 15.0 55.5
Melanoma
LOX IMV1 4.74 19.894 0.528 >100 >100 5.50 26.642 0.782 >100 >100 3.99 3.480 1.305 18.6 >100
MALME-3M 8.87 >100 >100 5.70 >100 >100 2.92 7.81 >100
M14 7.49 >100 >100 5.23 >100 >100 4.19 23.0 >100
MDA-MB-435 7.01 >100 >100 7.53 >100 >100 3.07 23.5 >100


























































































































SK-MEL-28 >100 >100 >100 >100 >100 >100 2.42 6.11 59.5
SK-MEL-5 4.10 >100 >100 6.97 >100 >100 3.10 12.9 >100
UACC-257 35.1 >100 >100 >100 >100 >100 4.57 46.6 >100
UACC-62 4.38 >100 >100 5.94 >100 >100 2.89 12.6 62.1
Ovarian cancer
IGROV1 5.94 13.591 0.772 >100 >100 4.45 41.433 0.503 >100 >100 4.18 4.390 1.035 16.7 86.8
OVCAR-3 12.8 >100 >100 >100 >100 >100 4.08 15.4 72.0
OVCAR-4 6.39 >100 >100 >100 >100 >100 3.15 17.9 >100
OVCAR-5 34.5 >100 >100 10.5 >100 >100 5.19 27.0 >100
OVCAR-8 8.66 >100 >100 17.6 >100 >100 5.23 31.0 >100
NCI/ADR-RES 22.5 >100 >100 52.3 >100 >100 5.66 47.0 >100
SK-OV-3 4.35 >100 >100 5.18 >100 >100 3.24 8.18 44.9
Renal cancer
786-O 23.5 6.370 1.648 >100 >100 14.9 4.343 4.797 >100 >100 2.44 2.361 1.923 5.31 60.5
A498 2.63 >100 >100 2.35 >100 >100 1.36 4.43 >100
ACHN 3.14 >100 >100 1.37 >100 >100 1.84 4.70 17.5
CAKI-1 2.52 >100 >100 1.01 >100 >100 1.74 4.30 12.8
RXF 393 4.55 >100 >100 3.47 >100 >100 1.94 4.15 8.88
SN12C 5.42 >100 >100 4.35 >100 >100 5.11 27.9 >100
TK-10 N.T. N.T. N.T. N.T. N.T. N.T. 2.46 8.08 48.0
UO-31 2.83 >100 >100 2.95 >100 >100 2.00 5.04 24.6
Prostate cancer
PC-3 5.93 5.360 1.959 >100 >100 4.35 5.925 3.516 >100 >100 2.93 3.295 1.378 10.2 50.5
DU-145 4.79 >100 >100 7.50 >100 >100 3.66 15.5 61.4
Breast cancer
MCF7 5.42 6.813 1.541 >100 >100 12.7 12.350 1.687 >100 >100 3.88 3.580 1.269 70.3 >100
MDA-MB-231/
ATCC
7.23 >100 >100 4.31 >100 >100 3.64 17.1 89.1
HS 578T 4.77 >100 >100 5.58 >100 >100 4.25 95.2 >100
BT-549 10.6 >100 >100 40.8 >100 >100 4.32 19.7 85.6
T-47D 8.44 >100 >100 4.57 >100 >100 3.92 39.7 >100
MDA-MB-468 4.42 >100 >100 6.14 >100 >100 1.47 4.73 48.6
MIDa 10.498 20.832 4.542





































































































































16 T.-C. Chen et al.2-(2-hydroxyethyl)anthra[1,9-cd]pyrazol-6(2H)-one (18–32)
(Scheme 1).
A series of 7-substituted anthra[1,9-cd]pyrazol-6(2H)-one
derivatives were synthesized and the preparation involved
various synthetic approaches with approximate yields (overall
14–75% in all steps) (Scheme 1). First, 1,5-
dichloroanthraquinone with hydrazine monohydrate and
DIPEA or with 2-hydroxyethylhydrazine and pyridine were
dissolved in DMSO and heated at 120 C for 2 h. Then, the
key intermediate 1/17 with a series of primary amines and 4-
dimethylaminopyridine (DMAP) yielded the corresponding
side chain compounds 2–16 and 18–32, respectively. The quan-
tity of all the synthetic compounds was dependent on sub-
strates and the by-products isolated that puriﬁes of the
reaction mixtures required tedious recrystallization from ethyl
acetate/n-hexane and/or ethanol. The protons and carbons
from anthrapyrazole structures were also obvious from the
1H NMR and 13C NMR spectra, respectively. The exact
molecular weight of all synthetic compounds 1–32 was deter-
mined using high resolution mass spectrometry (HRMS).
In SRB assay, four compounds (4, 12, 15, and 16) showed
potent cell cytotoxicity with the IC50 values less than 10 lM.
We found the pyrazole ring modiﬁed with a hydroxyethyl
group was failed to grasp the main points. And the substituted
side chains of anthrapyrazole derivatives were preferred benzy-
lamine side chains which were exhibited the outstanding cyto-
toxicity. All the synthetic compounds were investigated but
found none of the synthetic compounds showed signiﬁcant
repressive effects (data not shown).
According to the data from NCI 60 cancer cell lines, 28
could achieve inhibiting effects against breast cancer cell line
MDA-MB-468, up to 15.55%. Compound 16 (NSC764637)
was efﬁcacious against renal cancer cell strain RXF 393,
ACHN and TK-10, and could measure an inhibition effect
on the growth of the said cancer cells up to 15.19%,
5.18% and 6.44%, respectively. Besides, 16 also has impactful
against OVCAR-4 (ovarian cancer), SR (leukemia), HCT-116,
and KM12 (colon cancer) cell lines that could attain a growth
inhibition effect at 2.57%, 3.65%, 2.72% and 7.38%, sever-
ally. Compounds 4 and 16 were found that might have cyto-
toxic effect against Adriamycin (ADR)-resistance. The tested
compounds, which decrease the average of growth percentage
more than 33%, were picked out for further evaluation in the
nine major panel of NCI’s 60 human cancer cell lines. As
shown in Table 2, three compounds 1, 4 and 16 of the ﬁfteen
tested compounds in primary 60-cell panel assay showed sali-
ent cell growth inhibition were incubated for a advanced 60-
cell panel assay at ﬁve logarithm concentrations (102, 101,
100, 101 and 102 lM) and the consequences were indicated with
GI50, TGI and LC50.
Results of the research spread the initial in vitro observation
described in the data above and conﬁrm the importance and
signiﬁcance of anticancer activity. Compound 1 carrying with
a chlorine atom at 7-position exhibited relatively growth inhi-
bition activity but not cytotoxic activity. SP600125
(NSC75890), a well-known anthrapyrazole, has no substitu-
tion at 7-position and the average of GI50 over all NCI’s cell
lines is about 20.3 lM (from NCI Cancer Screen Data,
10/2009). Comparison to 4 with side chain –
NH(CH2)4CH2OH displayed relatively growth inhibition
activity but not cytotoxic activity. Compound 4 had also the
best potent activity against colon cancer KM12 with GI50 asPlease cite this article in press as: Chen, T.-C. et al., Synthesis and biological evaluatio
agents. Arabian Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.2015little as 0.54 lM, but LC50 and TGI with >100 lM. The nine
dose–response curves displayed that the renal cancer subpanel
was the most sensitive part for 4, with GI50 of seven renal can-
cer cell lines ranging from 1.01–14.9 lM. The prostate cancer
subpanel was the second most sensitive with GI50 between
4.35 and 7.50 lM. Moreover, it is especially notable that 16
with a bulky side chain (piperonylamine) was quite sensitive
for all subpanels (GI50 < 10 lM), except leukemia.
Compound 16 was also found that might have cytotoxic effect
against Adriamycin (ADR)-resistance cell line (NCI/ADR-
RES) at 5.66 lM. For all antitumor activity parameter in
NCI Drug Screen Program, the averaged values of mean graph
midpoint (MG-MID) were calculated over 60 cell lines.
As shown in Table 3 for compound 1, the average concen-
tration required to inhibit GI50 was 10.50 lM with a range of
2.50 lM (colon cancer: KM12) to >100 lM (melanoma: SK-
MEL-28). The average concentration of 4 required to inhibit
GI50 was 20.83 lM with a range of 0.54 lM (colon cancer:
KM12) to >100 lM (colon cancer: HCC-2998; CNS cancer:
SNB-19; melanoma: SK-MEL-28 and UACC-257; ovarian
cancer: OVCAR-3 and OVCAR-4). And the average concen-
tration of 16 required to inhibit GI50 was 4.52 lMwith a range
of 0.96 lM (colon cancer: KM12) to 56.4 lM (leukemia: HL-
60). In addition, >100 lM (104 M) was required to achieve
LC50 in the great majority of 60-human tumor cell lines, cell
line sensitive to 1 and 4, exhibited that both the values of
LC50 and TGI are more than 100 lM (10
4 M) (colon cancer:
KM12). And cell line sensitive to the other 16, exhibited an
LC50 with as little as 16.6 lM and also TGI with >100 lM
(colon cancer: KM12). Compounds 1, 4 and 16 showed
dose-dependent inhibition of proliferation in 60 tumor cell
lines. All the data were summarized in Table 3 and used for
further analysis. According to the ratio obtained by distin-
guishing the full panel MID (the average sensitivity of all cell
lines toward the test agent), the selected compounds showed
different selectivity (Noolvi et al., 2011). The values of selectiv-
ity ratio greater than 6 refer to high selectivity; values between
3 and 6 indicate moderately toward the homologous cell line,
while compounds are not in line with either of these criteria
accounted non-selective (Acton et al., 1994; Rostom, 2006).
On the basis of the selectivity ratio, 4 in the study was found
to be moderate selectivity for growth inhibition regarding renal
and prostate cancer subpanels with selectivity ratio of 4.797
and 3.516, otherwise it was found lower selectivity against
other cell panels (Table 3).5. Conclusion
As a summary, several heterocycle-fused anthrapyrazolone
derivatives, derived from 1 or 17, have been prepared by the
addition or substitution nucleophilic reactions, using
N-nucleophiles. Those anthrapyrazolone, with different sub-
stituents at the C-7 position, were further transformed into
the extended tetracyclic systems bearing nitrogen-heterocyclic
rings fused to the quinone moiety. The compounds synthesized
have been evaluated for their cytotoxic of cell growth inhibi-
tory effect and telomerase inhibitory activity. As expected,
analysis of tetracyclic core-structure derivatives might accord
further insight into designing better leading compounds for
anti-tumor therapies. Among the compounds tested as antitu-
mor in this work, the average GI50 of compounds 1 and 16n of anthra [1,9-cd]pyrazol-6(2H)-one scaﬀold derivatives as potential anticancer
.06.017
Synthesis and biological evaluation of anthra[1,9-cd]pyrazol-6(2H)-one scaffold derivatives 17were 10.498 and 4.542 lM over 60 cell lines. Based on the
structure of anthrapyrazolone, we found that particularity
for optimum antiproliferative activities are: (1) the
2-hydroxyethyl group at N-2 is decreased potency;
(2) substituent at C-7 is fond of the side chain which contains
oxygen atoms in the end but not an alkane one. However, the
pyrazole-fused anthraquinone system has shown no inhibitory
effect at the micromolar concentrations. Obviously, the
overall synthetic compounds showed no signiﬁcant correlation
between cytotoxicity and telomerase inhibition. In general, the
heterofused anthrapyrazolone were less active as cytotoxic
than their corresponding AQ precursors or intermediates with
the exception of the pyrazole-fused compounds that showed
positive results on the three biological tests. The compounds
might have the potential to be the leading compounds as
candidate drugs for anti-cancer agents even if the mechanism
of action of the anthrapyrazoles is still controversial now.Acknowledgments
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